Second chance: lymphoma patients get access to imperfect but potentially lifesaving CAR T-Cell therapy
NCT ID NCT04400591
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 24 times
Summary
This program gives people with large B-cell lymphoma access to a CAR T-cell therapy called lisocabtagene maraleucel (liso-cel) when their specific batch didn't pass all quality checks. Participants receive chemotherapy before the treatment. The goal is to offer a potential benefit when no other standard options are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.